Literature DB >> 2574458

Unusual stage-specific embryonic antigen (TEC-4) defined by a monoclonal antibody to embryonal carcinoma cells defective in the expression of embryoglycan.

P Dráber1, J Nosek, Z Pokorná.   

Abstract

Most developmentally regulated epitopes identified on embryonal carcinoma cells and murine preimplantation embryos are associated with a glycoprotein-bound large glycan called embryoglycan. To prepare monoclonal antibodies recognizing other, less immunogenic stage-specific embryonic epitopes, we used embryoglycan-negative embryonal carcinoma cells P19XT.1.1 as immunogen. One monoclonal antibody prepared by this strategy was found to react specifically with mouse embryonal carcinoma and embryo-derived stem cell lines. The target epitope, TEC-4, was found to be expressed on eggs and two-cell embryos but was undetectable on later stages of mouse embryos and adult mouse tissues. NaDodSO4/PAGE of immunoaffinity-isolated antigen revealed that TEC-4 epitope is associated with glycoproteins of apparent Mr 120,000 and 240,000. The epitope was resistant to oxidation by sodium periodate and to digestion by endoglycosidase F but was sensitive to treatment with protein-denaturing agents and proteases, which suggested that the epitope is located in the protein moiety of the molecule. In the course of retinoic acid-induced differentiation of embryonal carcinoma cells the epitope disappeared before the onset of morphological differentiation. The combined data indicate that TEC-4 is an unusual stage-specific embryonic antigen that may be amenable to direct genetic analysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574458      PMCID: PMC298490          DOI: 10.1073/pnas.86.23.9337

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Murine embryonal carcinoma cell-surface sialyl LeX is present on a novel glycoprotein and on high-molecular-weight lactosaminoglycan.

Authors:  S J Rosenman; B A Fenderson; S I Hakomori
Journal:  Exp Cell Res       Date:  1989-02       Impact factor: 3.905

2.  Alteration of cell-surface proteins by viral transformation and by proteolysis.

Authors:  R O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  1973-11       Impact factor: 11.205

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

6.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol.

Authors:  I Stefanová; I Hilgert; H Kristofová; R Brown; M G Low; V Horejsí
Journal:  Mol Immunol       Date:  1989-02       Impact factor: 4.407

Review 7.  Mouse teratocarcinoma and embryonic antigens.

Authors:  F Jacob
Journal:  Immunol Rev       Date:  1977-01       Impact factor: 12.988

8.  Isolation of male embryonal carcinoma cells and their chromosome replication patterns.

Authors:  M W McBurney; B J Rogers
Journal:  Dev Biol       Date:  1982-02       Impact factor: 3.582

9.  Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1).

Authors:  D Solter; B B Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  1 in total

1.  T cell response to embryonal carcinoma F9 cells: induction and characterization of T cell receptor alpha beta+ double-negative cytotoxic T lymphocytes.

Authors:  M Imada; S Fujimoto
Journal:  Jpn J Cancer Res       Date:  1993-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.